PERCIST	PET Response Criteria in Solid Tumors
PECRIT	PET/CT Criteria for Early Prediction of Response to Immune Checkpoint Inhibitor Therapy (combined RECIST 1.1 and PERCIST)
PERCIMT	PET Response Evaluation Criteria for Immunotherapy
CMR	complete metabolic response
PMR	partial metabolic response
SMD	stable metabolic disease
PMD	progressive metabolic disease
SULpeak	lean body mass corrected SUV peak
UPMD	unconfirmed progressive metabolic disease
CPMD	confirmed progressive metabolic disease.
RECIST	Response Evaluation Criteria in Solid Tumors
irRC	immune-related Response Criteria
CR	complete response
PR	partial response
SD	stable disease
PD	progressive disease
iUPD	initially unconfirmed progressive disease
iCPD	confirmed progressive disease
CB	clinical benefit
EORTC	European Organization for Research and Treatment of Cancer (EORTC5, includes the sum of SUVmax)
MTV	metabolic tumor volume
wbMTV	whole body MTV
TMTV	total metabolic tumor volume
WB-MATV	whole body metabolically active tumor volume
TLG	total lesions glycolysis
iDR	immune dissociated-response
ETD	early treatment discontinuation
BLR	bone marrow-to-liver SUVmax ratio
SLR	spleen-to-liver SUVmax ratio
dNLR	derived neutrophils-to-lymphocytes ratio
LDH	lactate dehydrogenase
FD	fractal dimension
ICI	immune checkpoint inhibitors
irAEs	immune-related adverse events
IMPI	immune-metabolic-prognostic index
ATB	antibiotic
ADC	apparent diffusion coefficient
SRE	Small Run Emphasis
mpRS	multiparametric radiomics signature
DLS	deeply learned score
DCB	durable clinical benefit
PFS	progression-free survival
OS	overall survival
DCR	disease control rate
ORR	overall response rate
Muc-M	mucosal melanoma
Cut-M	cutaneous melanoma
sPD-L1	soluble PD-L1.